Navigation Links
Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Date:10/25/2011

PITTSBURGH and POTTERS BAR, England, Oct. 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.K.-based subsidiary has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 mg and 6 mg. This product is the generic version of Novartis' Exelon® Capsules, a treatment for dementia in people with Alzheimer's disease. Mylan is the first company to launch a generic Rivastigmine formulation in the U.K.

Mylan Chairman and CEO Robert J. Coury said: "This is the second recent first-to-market generic for Mylan's business in the U.K., following the company's successful launch of Modafinil tablets, 100 mg, the generic version of Cephalon's Provigil®, earlier this year. We are excited to be adding generic Rivastigmine to our strong portfolio of more than 350 products in the U.K., and delivering on our brand's commitment of providing high quality and affordable medicines to patients around the world."

Rivastigmine Capsules POM had U.K. sales of approximately pounds Sterling 7.9 million for the last 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
2. Matrix Laboratories Completes Name Change to Mylan Laboratories
3. Mylan Announces Femcon® Fe Settlement Agreement
4. Mylan Announces Intention to Refinance Existing Secured Credit Facility
5. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
6. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
7. Mylan Announces XELODA® Settlement and License Agreement
8. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
9. Mylan Launches Generic Version of Uroxatral® Tablets
10. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
11. Mylan Launches First Generic Version of Entocort EC® Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)...  AMRI (NASDAQ:  AMRI) today announced that Anthony J. ... of Pfizer Global Supply, has been elected to the AMRI ... addition, the Company announced that Mr. Gabe Leung , ... has retired from the AMRI Board of Directors in order ... ventures.  William S. Marth , President and ...
(Date:2/4/2016)... , Feb. 4, 2016 SONIFI™ ... technology solutions, today announced that MonteCedro, an innovative ... Living Engagement System. The system provides a simple ... residents access through a tablet PC. ... resident engagement system provides access to a wide ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... ... ... Stuart Bentkover, MD, FACS is thrilled to announce the arrival of ... removal today, Dr. Bentkover is the only doctor in Central Massachusetts to offer patients ... approved by the Food and Drug Administration (FDA) as a safe and efficient method ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June ... Diseases, a continuing medical education (CME) event presented by the Association for Comprehensive ... a first for ACCORD, whose mission is to provide education, tools, and resources ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater ... having a tankless water heater. To view the report, click here or ... tankless. While each has their pros and cons, the type chosen is almost entirely ...
Breaking Medicine News(10 mins):